Core Viewpoint - Tonghua Dongbao Pharmaceutical Co., Ltd. is expected to achieve a net profit of approximately 1.242 billion yuan for the year 2025, marking a significant turnaround in performance and entering a new phase of high-quality development [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 1.242 billion yuan and a net profit of about 402 million yuan after deducting non-recurring gains and losses, both indicators showing a year-on-year turnaround [1] - The strong recovery in performance is attributed to product iteration, market expansion, R&D innovation, and improved corporate governance [1] Group 2: Market Dynamics - The domestic insulin market has undergone two rounds of procurement reshuffling, leading to an increase in domestic market share and an optimized competitive landscape [1] - Tonghua Dongbao's third-generation insulin sales have increased by over 100% year-on-year, contributing significantly to revenue and shifting the product structure towards a balanced development of both second and third-generation insulins [2] - The company holds a market share of 45.5% in second-generation insulin, maintaining its leadership position in the domestic market [2] Group 3: International Expansion - The company has seen a nearly 80% year-on-year growth in overseas revenue, with international business becoming a crucial growth driver [3] - Key international registrations include the acceptance of the aspart insulin BLA by the FDA, marking a significant step into high-end markets [3] - The company has successfully registered various insulin products in multiple countries, enhancing its international competitiveness [3] Group 4: R&D Innovation - Tonghua Dongbao has increased its R&D efforts, achieving significant progress in several core projects, including the completion of Phase III clinical trials for semaglutide [4] - The company is advancing its pipeline in metabolic disease treatments, with promising results in clinical trials for various products [4] Group 5: Corporate Governance - The company has launched an employee stock ownership plan to align the interests of shareholders, the company, and key employees, enhancing team cohesion and core competitiveness [5] - The controlling shareholder has increased its stake by 228 million yuan, reflecting confidence in the company's future [5] - The company plans to repurchase shares worth 20 to 40 million yuan to support the employee stock ownership plan, stabilizing market expectations [5] Group 6: Future Outlook - Looking ahead, the company aims to solidify its domestic insulin market position, optimize product structure, and expand market share [6] - The company will accelerate its international strategy and enhance its global value chain capabilities [6] - Continued focus on innovation and expanding its product portfolio in metabolic disease treatment is expected to showcase the company's resilience and industry leadership [7]

Group 1: Earnings Forecasts - Tonghua Dongbao expects a net profit of approximately 1.242 billion yuan for 2025, turning from loss to profit compared to the previous year [3] - Duofuduo anticipates a net profit of 200 million to 280 million yuan for 2025, recovering from a loss of 308 million yuan in the previous year [3] - China Rare Earth forecasts a net profit of 143 million to 185 million yuan for 2025, compared to a loss of 287 million yuan in the previous year [3] - Xianda Co. expects a net profit of 135 million to 155 million yuan for 2025, turning from loss to profit compared to the previous year [3] - Aorui De anticipates a net profit of 120 million to 160 million yuan for 2025, recovering from a loss in the previous year [3] - Maide Medical forecasts a net profit of approximately 66.52 million yuan for 2025, turning from loss to profit compared to the previous year [3] - Boliwei expects a net profit of approximately 59 million yuan for 2025, turning from loss to profit compared to the previous year [3] - Weixin Bio anticipates a net profit of approximately 53.46 million yuan for 2025, recovering from a loss in the previous year [3] - Decai Co. forecasts a net profit of 51 million to 61 million yuan for 2025, turning from loss to profit compared to the previous year [3] - Far East Co. expects a net profit of 45 million to 65 million yuan for 2025, recovering from a loss in the previous year [3] - Optoelectronics Co. anticipates a net profit of 45 million to 55 million yuan for 2025, turning from loss to profit compared to the previous year [3] - Baiyang Co. forecasts a net profit of 41 million to 52 million yuan for 2025, recovering from a loss of 15.25 million yuan in the previous year [3] Group 2: Significant Increases in Earnings - Youhao Group expects a net profit increase of 357% to 420% for 2025 [3] - Ningbo Dongli anticipates a net profit increase of 324.74% to 346.53% for 2025 [3] - SanSheng Guojian forecasts a net profit increase of approximately 311.35% for 2025 [3] - Jixin Technology expects a net profit increase of 277.15% to 454.09% for 2025 [3] - Pulite anticipates a net profit increase of 155.76% to 194.73% for 2025 [3] - Yixin Hall expects a net profit increase of 127.79% to 189.12% for 2025 [3] - Bangji Technology forecasts a net profit increase of 119.43% to 169.3% for 2025 [3] - Xinlian Electronics anticipates a net profit increase of 106.8% to 129.11% for 2025 [3] Group 3: Fundraising and Restructuring - Zhejiang Haideman plans to raise no more than 1.517 billion yuan through a private placement [11] - Anlu Technology intends to raise no more than 1.262 billion yuan through a private placement [11] - Chuanhuan Technology plans to raise no more than 1 billion yuan through a private placement [11] - Zijin Mining intends to acquire 100% of Allied Gold for approximately 28 billion yuan [11][16] Group 4: Major Events - Haike New Source signed a long-term cooperation agreement with BYD Lithium Battery to supply at least 100,000 tons of products annually [10] - Jinfei Kaida received a supplier designation from a well-known international automobile manufacturer [17] - Jiangzhong Pharmaceutical will change its stock name to "China Resources Jiangzhong" starting January 30, 2026 [17]

通化东宝表示，本次业绩预盈的主要原因为，公司依托本次胰岛素集采中标优势，推动门冬、甘精等胰 岛素类似物产品快速上量，市场份额迅速提升，同时，利拉鲁肽注射液与恩格列净片等产品同样取得良 好增长，多品类协同发力，带动国内销售收入较上期大幅攀升。国际上，公司国际化战略成效显著，出 口收入增长明显。此外，公司转让厦门特宝生物工程股份有限公司股权产生收益，导致净利润大幅增 加。 （文章来源：北京商报） 北京商报讯1月26日晚间，通化东宝（600867）发布2025年业绩预告显示，经公司财务部门初步测算， 预计2025年实现归属净利润约为12.42亿元，与上年同期相比，将实现扭亏为盈。 ...

（文章来源：证券日报） 证券日报网讯 1月26日，通化东宝发布公告称，公司预计2025年年度实现归属于母公司所有者的净利润 约为124213万元，与上年同期相比，将实现扭亏为盈。 ...

Core Viewpoint - Tonghua Dongbao (600867) is expected to achieve a net profit of approximately 1.242 billion yuan and a net profit of approximately 402 million yuan after deducting non-recurring gains and losses in 2025, marking a significant turnaround from previous losses and a substantial recovery in performance [1] Group 1: Financial Performance - In 2025, the company anticipates a significant recovery in its financial performance, with both net profit and adjusted net profit turning positive compared to the previous year [1] - The company’s insulin similar products are projected to drive major growth, with annual sales expected to increase by over 100% year-on-year, contributing to a balanced development of its product structure [1][2] Group 2: Market Position and Strategy - Tonghua Dongbao has achieved significant improvements in market share, ranking second in the industry for human insulin and insulin similar products, with a market share of 45.5% for human insulin, maintaining the leading position domestically [2] - The company is focusing on enhancing its domestic insulin business, optimizing product structure, and expanding market share while accelerating its internationalization strategy [1][2] Group 3: Product Development and Innovation - The company has made substantial progress in international product registration, with various insulin formulations and GLP-1 products receiving approvals in multiple countries, including the U.S., Dominican Republic, and Indonesia [3] - Several R&D projects have achieved important clinical milestones, including the completion of Phase III trials for semaglutide and positive results for other diabetes-related products [4] Group 4: Shareholder Engagement - The controlling shareholder, Dongbao Industrial Group, has increased its stake in the company by investing 228 million yuan to acquire 1.42% of the shares, reflecting confidence in the company's future prospects [5] - The company plans to repurchase shares worth between 20 million and 40 million yuan to support employee stock ownership plans and/or equity incentives [5]

Core Viewpoint - Tonghua Dongbao is expected to achieve a significant turnaround in its financial performance for 2025, with a projected net profit of approximately 1.242 billion yuan and a net profit excluding non-recurring gains of about 402 million yuan, both showing a substantial recovery compared to the previous year [1] Group 1: Performance Highlights - The company's insulin analog products are experiencing rapid growth, with sales increasing by over 100% year-on-year, becoming the main driver of revenue growth [2] - In Q3 2025, revenue from insulin analogs surpassed that of traditional human insulin, marking a key milestone in product upgrade [2] - Tonghua Dongbao's market share in the insulin sector remains second in the industry, with human insulin market share rising to 45.5%, maintaining the leading position domestically [2] Group 2: R&D Progress - The company is increasing R&D investment, advancing multiple innovative drug projects in the metabolic disease field [3] - Significant progress has been made with GLP-1 drugs, including the completion of Phase III clinical trials for semaglutide and positive results from Ib phase trials for a GLP-1/GIP dual-target agonist [3] - The company is also accelerating the development of insulin combination formulations and has received marketing approval for a gout drug, showcasing a diversified pipeline [3] Group 3: International Expansion - Tonghua Dongbao's internationalization has accelerated, with several core products achieving registration and market access breakthroughs in emerging markets [4] - The company is implementing a dual-output model of "raw materials + formulations," with significant progress in the internationalization of insulin analogs and human insulin [4] - The strategy includes breakthroughs in mature markets and rapid access in emerging markets, gradually building a sales network across multiple regions [4] Group 4: Shareholder Returns and Talent Incentives - The controlling shareholder, Dongbao Industrial Group, has increased its stake by 228 million yuan, reflecting confidence in the company's future [5] - The company plans to repurchase shares worth 20 to 40 million yuan for employee stock ownership or equity incentives, aiming to align interests among shareholders, the company, and employees [6] Group 5: Value Reassessment - Experts believe that as the revenue share of insulin analogs continues to rise, Tonghua Dongbao's profit structure and growth quality are expected to improve further [7] - The company is constructing a new growth pattern through the volume increase of insulin analogs, gradual realization of innovative drugs, and accelerated internationalization [7]

国内市场方面，公司依托本次胰岛素集采中标优势，推动门冬、甘精等胰岛素类似物产品快速上量，市 场份额迅速提升;同时，利拉鲁肽注射液与恩格列净片等产品同样取得良好增长，多品类协同发力，带 动国内销售收入较上期大幅攀升。 智通财经APP讯，通化东宝(600867.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净 利润约为12.42亿元，与上年同期相比，将实现扭亏为盈。 ...

2024年，通化东宝的利润总额为-1.44亿元，归属于母公司所有者的净利润-4272.32万元，归属于母公司 所有者的扣除非经常性损益的净利润-919.54万元。 通化东宝（600867）1月26日晚发布2025年年度业绩预盈公告，经公司财务部门初步测算，预计2025年 实现归属于母公司所有者的净利润约为12.42亿元，与上年同期相比，将实现扭亏为盈。预计2025年实 现归属于母公司所有者的扣除非经常性损益的净利润约为4.02亿元。 通化东宝在2025年第三季度业绩说明会上介绍，2025年以来，公司国际化战略稳步推进，国际注册呈现 出扩面提速、多点开花的良好局面。 胰岛素方面，在新兴市场，公司胰岛素制剂产品已先后在乌兹别克斯坦、尼加拉瓜、缅甸、印尼、多米 尼加5个国家获批上市；在法规市场，公司门冬胰岛素美国BLA已获得美国食品药品监督管理局(FDA) 受理，后续将继续推进甘精胰岛素和赖脯胰岛素的BLA申报工作，并有序开展胰岛素类似物在欧洲 和"一带一路"共建国家的注册资料准备及申请工作。 GLP-1方面，公司与科兴制药合作开拓利拉鲁肽注射液海外市场，已通过埃及卫生部GMP现场审计并获 得哥伦比亚GMP证书，同 ...

每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 （记者 曾健辉） 每经AI快讯，通化东宝1月26日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 约为12.42亿元，与上年同期相比，将实现扭亏为盈。业绩变动主要原因是，主营业务影响。国内市场 方面，公司依托本次胰岛素集采中标优势，推动门冬、甘精等胰岛素类似物产品快速上量，市场份额迅 速提升；同时，利拉鲁肽注射液与恩格列净片等产品同样取得良好增长，多品类协同发力，带动国内销 售收入较上期大幅攀升。公司国际化战略成效显著，出口收入增长明显。非经营性损益的影响。公司转 让厦门特宝生物工程股份有限公司股权产生收益，导致净利润大幅增加。 ...

证券代码：600867 证券简称：通化东宝 公告编号：2026-009 通化东宝药业股份有限公司 关于计提减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 通化东宝药业股份有限公司（以下简称"公司"）于2026年1月26日召开第十一届 董事会第二十二次会议，审议通过了《关于计提减值准备的议案》，为了更加客观、公 正地反映公司财务状况和资产价值，根据《企业会计准则》等相关规定，结合企业实际 经营情况和资产现状，对截至2025年12月31日的相关资产进行了减值迹象的识别，对于 其中已出现减值迹象的进行了减值测试，并根据测试结果计提相关资产减值准备，在 2025年1-9月已计提资产减值准备的基础上，公司2025年10-12月计提减值准备的具体情 况如下： 一、本次计提资产减值准备情况概述 根据《企业会计准则第1号——存货》《企业会计准则第 8 号 —— 资产减值》 《企业会计准则第 22 号 —— 金融工具确认和计量》等相关规定以及公司的实际业务 情况，对公司截至2025年12月31日的合并范围内相关资产进行减值测试， ...